Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [41] Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study
    Uemura, Hirotsugu
    Arai, Gaku
    Uemura, Hiroji
    Suzuki, Hiroyoshi
    Iijima, Kazuyoshi
    Nishimura, Kazuo
    Fujii, Koji
    Hatayama, Tomoyoshi
    Aoyama, Junya
    Deprince, Kris
    Lopez-Gitlitz, Angela
    McCarthy, Sharon
    Larsen, Julie S.
    Li, Jinhui
    Chi, Kim N.
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (03) : 280 - 287
  • [42] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
    Chehrazi-Raffle, Alex
    Morgans, Alicia K.
    Gschwend, Jurgen E.
    Shore, Neal D.
    Ross, Ashley
    Feng, Felix Y.
    Hope, Thomas A.
    Trandafir, Lucia
    Kuss, Iris
    Le Berre, Marie-Aude
    Joensuu, Heikki
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS254 - TPS254
  • [43] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
    Morgans, Alicia K.
    Niazi, Tamim
    Shore, Neal D.
    Gschwend, Juergen E.
    Ross, Ashley
    Hope, Thomas A.
    Chehrazi-Raffle, Alex
    Supiot, Stephane
    Barthelemy, Philippe
    Roder, Andreas
    Gomes, Andrea Juliana
    Imbroda, Bernardo Herrera
    Gratton, Matthieu
    Ruiz, Carmen Belen Congregado
    Joensuu, Heikki
    Dimova-Dobreva, Miryana
    Le Berre, Marie-Aude
    Kuss, Iris
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS432 - TPS432
  • [44] Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
    Kantoff, Philip W.
    Gulley, James L.
    Pico-Navarro, Cesar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 124 - +
  • [45] Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
    Ryan, Charles J.
    Smith, Matthew R.
    Fizazi, Karim
    Saad, Fred
    Mulders, Peter F. A.
    Sternberg, Cora N.
    Miller, Kurt
    Logothetis, Christopher J.
    Shore, Neal D.
    Small, Eric J.
    Carles, Joan
    Flaig, Thomas W.
    Taplin, Mary-Ellen
    Higano, Celestia S.
    de Souza, Paul
    de Bono, Johann S. s
    Griffin, Thomas W.
    De Porre, Peter
    Yu, Margaret K.
    Park, Youn C.
    Li, Jinhui
    Kheoh, Thian
    Naini, Vahid
    Molina, Arturo
    Rathkopf, Dana E.
    LANCET ONCOLOGY, 2015, 16 (02): : 152 - 160
  • [46] Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
    Kwon, Whi-An
    Joung, Jae Young
    Lee, Jung Eun
    Choi, Se Young
    Kim, Sung Han
    Seo, Ho Kyung
    Lee, Kang Hyun
    Kim, Choung-Soo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2019, 60 (03) : 195 - 201
  • [47] A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer
    Palmbos, Phillip L.
    Daignault-Newton, Stephanie
    Tomlins, Scott A.
    Agarwal, Neeraj
    Twardowski, Przemyslaw
    Morgans, Alicia K.
    Kelly, Wm. Kevin
    Arora, Vivek K.
    Antonarakis, Emmanuel S.
    Siddiqui, Javed
    Jacobson, Jon A.
    Davenport, Matthew S.
    Robinson, Dan R.
    Chinnaiyan, Arul M.
    Knudsen, Karen E.
    Hussain, Maha
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3017 - 3027
  • [48] Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.
    Azad, Arun
    Iguchi, Taro
    Alekseev, Boris
    Shore, Neal D.
    Sugg, Jennifer
    Haas, Gabriel P.
    Wozniak, Michele
    O'Brien, Thomas
    Laird, Douglas
    Stenzl, Arnulf
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation
    Choi, Young Hyo
    Han, Deok Hyun
    Kim, Seon-woo
    Kim, Min-ji
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Choi, Han Yong
    PROSTATE, 2019, 79 (06): : 614 - 621
  • [50] OUTCOMES BY PROSTATE-SPECIFIC ANTIGEN LEVEL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY AND IMPLICATIONS FOR CLINICAL PRACTICE
    Huebner, Tamara
    Williams, Monique
    Shore, Neal
    El-Chaar, Nader
    Russell, David
    Armstrong, Andrew
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
12345